Literature DB >> 32032633

Dual biomarkers long non-coding RNA GAS5 and its target, NR3C1, contribute to acute myeloid leukemia.

Fereshteh Nasiri Ganjineh Ketab1, Jalal Gharesouran2, Soudeh Ghafouri-Fard3, Saba Dastar4, Shamsi Abdi Mazraeh1, Hassan Hosseinzadeh5, Mohsen Moradi6, Masoumeh Javadlar1, Amirataollah Hiradfar7, Azim Rezamand7, Mohammad Taheri8, Maryam Rezazadeh9.   

Abstract

Acute myeloid leukemia (AML) is a complex hematological neoplasm with poor prognosis. At present, overwhelming evidence indicates that different genetic abnormalities are relevant to the pathogenesis of AML. Nevertheless, its exact molecular mechanism is still unknown. Recently, it was reported that lncRNAs play crucial roles in tumorigenesis. But, their role in the molecular pathogenesis of AML has not been extensively explored. GAS5, one of the earliest known lncRNAs, has an essential role in the formation and progression of multiple human cancers. It was recently demonstrated that GAS5 acts as a riborepressor of the Glucocorticoid receptor) GR) and abnormal levels of GAS5 may alter response of hematopoietic cells to glucocorticoids. GAS5 can have interaction with the GR that encoded by NR3C1 gene and inhibit its transcriptional activity. To test whether the genetic variants can be associated with AML risk, we genotyped rs55829688 (T > C) polymorphism in GAS5 and three NR3C1 SNPs namely rs6195, rs41423247 and rs6189/rs6190 in a population of 100 Iranian AML patients and 100 healthy subjects. The analysis of the data showed the frequency of alleles and genotypes of rs55829688 and rs6189/rs6190 polymorphisms did not differ between patients and healthy subjects. But, rs41423247 and rs6195 demonstrated a significant correlation with AML risk. The rs6195 was associated with higher AML susceptibility in the co-dominant (OR = 4.58, 95% CI = 2.11-9.981, P < .0001), dominant (OR = 4.55, 95% CI = 2.155-9.613, P < .0001), and over-dominant (OR = 4.43, 95% CI = 2.042-9.621, P < .0001) models. Also, the rs41423247 polymorphism was associated with higher risk of AML in co-dominant (OR = 2.07, 95% CI = 1.171-4.242, P = .012) and dominant (OR = 2.47, 95% CI = 1.192-5.142, P = .010) models. Furthermore, haplotype analysis (rs41423247, rs6189.rs6190, rs6195, and rs55829688 respectively) demonstrated that GGAT, CGGT, and GGGT haplotypes were associated with higher risk of AML in the studied population (p-values = .007, 0.042 and 0.044, respectively). The present study reveals a possible role for NR3C1 in the pathogenesis of AML.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AML; GAS5; NR3C1; Polymorphism; lncRNA

Mesh:

Substances:

Year:  2020        PMID: 32032633     DOI: 10.1016/j.yexmp.2020.104399

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  4 in total

1.  GAS5/METTL14/ESR1 genetic variants are related to the susceptibility of coronary heart disease.

Authors:  Yuxiao Sun; Zhaoyun Cheng; Mingxia Cui; Yan Chen; Ruigang Xie; Guoqing Lu; Chuanyu Gao
Journal:  Funct Integr Genomics       Date:  2022-03-02       Impact factor: 3.410

Review 2.  GAS5‑mediated regulation of cell signaling (Review).

Authors:  Yang Zhou; Binghai Chen
Journal:  Mol Med Rep       Date:  2020-08-19       Impact factor: 2.952

3.  lncRNA GAS5 Induces Cell Apoptosis in Acute Myeloid Leukemia by Targeting Nrf2.

Authors:  Xiaohua Qin; Yanling Jiang; Xiaojun Zhang; Dan Li
Journal:  Dis Markers       Date:  2022-08-24       Impact factor: 3.464

4.  Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients.

Authors:  Djordje Pavlovic; Natasa Tosic; Branka Zukic; Zlatko Pravdic; Nada Suvajdzic Vukovic; Sonja Pavlovic; Vladimir Gasic
Journal:  Diagnostics (Basel)       Date:  2021-12-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.